Artelo Net Income From Continuing Ops from 2010 to 2024

ARTL Stock  USD 1.11  0.02  1.77%   
Artelo Biosciences Net Loss yearly trend continues to be quite stable with very little volatility. Net Loss may rise above about -8.8 M this year. From the period between 2010 and 2024, Artelo Biosciences, Net Loss regression line of its data series had sample variance of 15.7 T and sample variance of 15.7 T. View All Fundamentals
 
Net Loss  
First Reported
2017-09-30
Previous Quarter
-2.4 M
Current Value
-1.1 M
Quarterly Volatility
840.9 K
 
Covid
Check Artelo Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artelo Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.46. Artelo financial statements analysis is a perfect complement when working with Artelo Biosciences Valuation or Volatility modules.
  
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

Latest Artelo Biosciences' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Artelo Biosciences over the last few years. It is Artelo Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artelo Biosciences' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Artelo Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(3,024,216)
Coefficient Of Variation(131.08)
Mean Deviation3,382,711
Median(234,889)
Standard Deviation3,964,271
Sample Variance15.7T
Range10.3M
R-Value(0.88)
Mean Square Error3.8T
R-Squared0.78
Significance0.000014
Slope(781,766)
Total Sum of Squares220T

Artelo Net Income From Continuing Ops History

2024-8.8 M
2023-9.3 M
2022-10.3 M
2021-7.4 M
2020-4.7 M
2019-2.2 M
2018-2.3 M

About Artelo Biosciences Financial Statements

Artelo Biosciences investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Artelo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-9.3 M-8.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.87)
Return On Assets
(0.54)
Return On Equity
(0.89)
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.